2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK
  5. CDK Degrader

CDK Degrader

CDK Isoform Comparison

CDK Degraders (20):

Cat. No. Product Name Effect Purity
  • HY-151110A
    PROTAC CDK12/13 Degrader-1 TFA
    		Degrader 98.37%
    PROTAC CDK12/13 Degrader-1 (7f) TFA is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 TFA has anti-proliferative activity and can be used in breast cancer research.
  • HY-148530
    YX-2-107
    		Degrader 99.79%
    YX-2-107 is a PROTAC (IC50= 4.4 nM) that selectively degrades CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph+ ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
  • HY-149209
    LL-K8-22
    		Degrader 99.76%
    LL-K8-22 is a potent, selective and durable CDK8-cyclin C dual degrader, with DC50 values of 2.52 and 2.64 μM, respectively. LL-K8-22 also suppresses STAT1 Ser 727 phosphorylation. LL-K8-22 inhibits E2F- and MYC-driven carcinogenic transcriptional programs. LL-K8-22 can be used for triplenegative breast cancer (TNBC) research.
  • HY-153278
    CDK7-IN-21
    		Degrader
    CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor.
  • HY-160501
    DS17
    		Degrader 98.81%
    DS17 is a molecular glue that acts as a potent degrader of cyclin K, with an EC50 of 13 nM. DS17 plays an important role in cancer research.
  • HY-151110
    PROTAC CDK12/13 Degrader-1
    		Degrader
    PROTAC CDK12/13 Degrader-1 (7f) is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 has anti-proliferative activity and can be used in breast cancer research.
  • HY-163786
    PROTAC CDK4/6 degrader 1
    		Degrader 98.88%
    PROTAC CDK4/6 degrader 1 (Compound 7f) is a dual degrader for CDK4 and CDK6 with DC50 of 10.5 and 2.5 nM. PROTAC CDK4/6 degrader 1 inhibits the proliferation of cell Jurkat (IC50 is 0.18 μM), arrests the cell cycle at G1 phase and induces apoptosis. (Pink: ligand for target protein YY173 (HY-163787); Black: linker (HY-163788); Blue: ligand for E3 ligase (HY-10984))
  • HY-163815
    CDK2 degrader 2
    		Degrader
    CDK2 degrader 2 is a PROTAC class CDK2 degrader. The CDK2 binding moiety (CBM) binds to the CDK2 protein and subsequently undergoes ubiquitination, leading to the degradation of CDK2 through the ubiquitin proteasome pathway (UPP). CDK2 degrader 2 can cause degradation of CDK2 in MKN1 cells, with a DC50 value less than 100 nM and an average Dmax value greater than 75%. (Red: CBM; Blue: DIM; Black: linker)
  • HY-156084
    LL-K9-3
    		Degrader
    LL-K9-3 is a potent small-molecule degrader of CDK9-cyclin T1. LL-K9-3 has anti-proliferative and pro-apoptotic activities and suppresses downstream signaling of CDK9 and AR. Moreover, LL-K9-3 inhibits AR and Myc-driven oncogenic transcriptional programs.
  • HY-149495
    CP-07
    		Degrader
    CP-07 is a potent and selective PROTACCDK9 degrader (DC50: 43 nM). CP-07 inhibits 22RV1 cell proliferation (IC50: 62 nM) and colony formation by down-regulating Mcl-1 and c-Myc. CP-07 inhibits 22RV1 xenograft tumor growth. CP-07 can be used for research of prostate cancer.
  • HY-148521
    PROTAC FLT3/CDK9 degrader-1
    		Degrader
    PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and CDK9 dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML.
  • HY-161828
    JWZ-5-13
    		Degrader
    JWZ-5-13 is a potent CDK7 degrader that significantly degrades CDK7 through the ubiquitin-proteasome system. JWZ-5-13 has antitumor activity.
  • HY-168057
    PROTAC CDK2 Degrader-1
    		Degrader
    PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC50 of 100-500 nM.
  • HY-161709
    FLT3/CDKs ligand-1
    		Degrader
    FLT3/CDKs ligand-1 (Compound 14) is a ligand for target protein, which promotes the degradation of cyclin-dependent kinase (CDK) and the FMS-like tyrosine kinase 3 (FLT3), inhibits FLT3/CDK related proliferations and survivals of leukemia cells. LT3/CDKs ligand-1 can be used for synthesis of PROTAC FLT3/CDKs degrader-1 (HY-161708).
  • HY-163640
    CDK4 degrader 1
    		Degrader
    CDK4 degrader 1 (ML 1–71) is a monovalent degrader targeting CDK4.
  • HY-162706
    BSJ-5-63
    		Degrader
    BSJ-5-63 is a potent CDK12, CDK7, CDK9 degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer.
  • HY-161708
    PROTAC FLT3/CDKs degrader-1
    		Degrader
    PROTAC FLT3/CDKs degrader-1 (Compound C3) is a degrader for cyclin-dependent kinases (DC50 is 18.73 nM for CDK2) and the FMS-like tyrosine kinase 3 (FLT3). PROTAC FLT3/CDKs degrader-1 induces differentation of HL-60 (72.77% differentation at 6.25 nM), inhibits proliferation of AML cells, with IC50s of 2.9-37 nM. PROTAC FLT3/CDKs degrader-1 is potential for ameliorating acute myeloid leukemia. (Pink: ligand for target protein FLT3/CDKs ligand-1 (HY-161709); Black: linker (HY-W012935); Black: ligand for E3 ligase Thalidomide 5-fluoride (HY-W087383))
  • HY-164399
    SST0116CL1
    		Degrader
    SST0116CL1 is a HSP90 inhibitor (IC50: 0.21 μM). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 induces degradation of Her2 in BT-474 cell (IC50: 0.2 μM). SST0116CL1 has antiproliferative activity and inhibits tumor growth.
  • HY-115729A
    (R)-PROTAC CDK9 ligand-1
    		Degrader
    (R)-PROTAC CDK9 ligand-1 (Compound 19.4) is a CDK9-targeting degrader that can be used to synthesize PROTAC with antitumor activity.
  • HY-168163
    CDK12/13 ligand 1
    		Degrader
    ALK-IN-29 (compound 4c) has a certain inhibitory effect on tyrosine protein kinases ALK, CDK2/CyclinE1 and FAK, among which the strongest inhibitory effect on ALK kinase is 40.63% at a concentration of 10 μM. ALK-IN-29 can be used for anti-cancer research.